A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)

on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG)

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. The primary endpoint is overall survival, and the main objective is to confirm the non-inferiority of lobe-specific in comparison to systematic nodal dissection with regard to lobectomy. The secondary endpoints are relapse-free survival, %local recurrence, %regional lymph node recurrence, operation time, blood loss, length of hospitalization, duration of chest tube placement and adverse events. A total of 1700 patients will be accrued from 44 Japanese institutions within 5 years. This study is the first and large prospective trial to evaluate whether the difference in the area of nodal dissection affects the overall survival of patients with relatively early-stage non-small cell lung cancer. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025530.

Original languageEnglish
Pages (from-to)190-194
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume48
Issue number2
DOIs
Publication statusPublished - 2018 Feb 1

Fingerprint

Non-Small Cell Lung Carcinoma
Dissection
Recurrence
Survival
Chest Tubes
Medical Oncology
Registries
Lung Neoplasms
Japan
Hospitalization
Lymph Nodes
Clinical Trials

Keywords

  • Lobe-specific
  • Lymph node dissection
  • Non-small-cell lung cancer
  • Randomized Phase III study
  • Systematic

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413). / on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG).

In: Japanese Journal of Clinical Oncology, Vol. 48, No. 2, 01.02.2018, p. 190-194.

Research output: Contribution to journalArticle

on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG) 2018, 'A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)', Japanese Journal of Clinical Oncology, vol. 48, no. 2, pp. 190-194. https://doi.org/10.1093/jjco/hyx170
on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG). / A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413). In: Japanese Journal of Clinical Oncology. 2018 ; Vol. 48, No. 2. pp. 190-194.
@article{1ec23288f631430da0c7178d68f9c3b4,
title = "A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)",
abstract = "In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. The primary endpoint is overall survival, and the main objective is to confirm the non-inferiority of lobe-specific in comparison to systematic nodal dissection with regard to lobectomy. The secondary endpoints are relapse-free survival, {\%}local recurrence, {\%}regional lymph node recurrence, operation time, blood loss, length of hospitalization, duration of chest tube placement and adverse events. A total of 1700 patients will be accrued from 44 Japanese institutions within 5 years. This study is the first and large prospective trial to evaluate whether the difference in the area of nodal dissection affects the overall survival of patients with relatively early-stage non-small cell lung cancer. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025530.",
keywords = "Lobe-specific, Lymph node dissection, Non-small-cell lung cancer, Randomized Phase III study, Systematic",
author = "{on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG)} and Tomoyuki Hishida and Hisashi Saji and Watanabe, {Shun Ichi} and Hisao Asamura and Keiju Aokage and Tomonori Mizutani and Masashi Wakabayashi and Taro Shibata and Morihito Okada",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/jjco/hyx170",
language = "English",
volume = "48",
pages = "190--194",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413)

AU - on behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG)

AU - Hishida, Tomoyuki

AU - Saji, Hisashi

AU - Watanabe, Shun Ichi

AU - Asamura, Hisao

AU - Aokage, Keiju

AU - Mizutani, Tomonori

AU - Wakabayashi, Masashi

AU - Shibata, Taro

AU - Okada, Morihito

PY - 2018/2/1

Y1 - 2018/2/1

N2 - In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. The primary endpoint is overall survival, and the main objective is to confirm the non-inferiority of lobe-specific in comparison to systematic nodal dissection with regard to lobectomy. The secondary endpoints are relapse-free survival, %local recurrence, %regional lymph node recurrence, operation time, blood loss, length of hospitalization, duration of chest tube placement and adverse events. A total of 1700 patients will be accrued from 44 Japanese institutions within 5 years. This study is the first and large prospective trial to evaluate whether the difference in the area of nodal dissection affects the overall survival of patients with relatively early-stage non-small cell lung cancer. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025530.

AB - In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. The primary endpoint is overall survival, and the main objective is to confirm the non-inferiority of lobe-specific in comparison to systematic nodal dissection with regard to lobectomy. The secondary endpoints are relapse-free survival, %local recurrence, %regional lymph node recurrence, operation time, blood loss, length of hospitalization, duration of chest tube placement and adverse events. A total of 1700 patients will be accrued from 44 Japanese institutions within 5 years. This study is the first and large prospective trial to evaluate whether the difference in the area of nodal dissection affects the overall survival of patients with relatively early-stage non-small cell lung cancer. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000025530.

KW - Lobe-specific

KW - Lymph node dissection

KW - Non-small-cell lung cancer

KW - Randomized Phase III study

KW - Systematic

UR - http://www.scopus.com/inward/record.url?scp=85042913073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042913073&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx170

DO - 10.1093/jjco/hyx170

M3 - Article

VL - 48

SP - 190

EP - 194

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 2

ER -